| Brigham and Women's Hospital | |
|---|---|
| Location | Boston, Massachusetts, USA |
| Type | Teaching Hospital |
| Founded | 1914 |
| Affiliation | Harvard Medical School |
| Website | brighamandwomens.org |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, Women's Brain Health, Dementia, Movement Disorders |
Brigham and Women's Hospital (BWH) is a premier teaching hospital of Harvard Medical School, located in Boston, Massachusetts. Founded in 1914 through the merger of Peter Bent Brigham Hospital and other predecessor institutions, BWH has become a world-renowned center for medical research and clinical care, with significant programs in neuroscience and neurodegenerative disease research[1].
The hospital's Department of Neurology conducts comprehensive research on Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, with unique expertise in understanding sex differences in neurodegeneration and women's brain health. BWH researchers have made fundamental discoveries in disease mechanisms and developed novel therapeutic approaches[2].
Brigham and Women's Hospital is part of Mass General Brigham, the largest health care system in New England, which provides seamless access to cutting-edge research across multiple academic medical centers. This integration enables BWH to serve as a hub for neurodegenerative disease research, connecting basic science discoveries with clinical implementation.
BWH has a long history of medical innovation that has shaped its current status as a leader in neurodegenerative disease research:
The history of BWH is closely tied to the broader Harvard neuroscience community. Researchers at BWH, particularly in the Department of Neurology, have been central to the evolution of the amyloid hypothesis of Alzheimer's disease since the late 1980s[3].
BWH maintains a comprehensive Alzheimer's disease research program that spans from basic science to clinical implementation:
Amyloid Biology and Target Validation
The landmark work of Dr. Dennis Selkoe and colleagues established the foundational understanding of amyloid-beta (Aβ) metabolism in Alzheimer's disease. Key discoveries include:
Prevention and Early Detection
Dr. Reisa Sperling leads pioneering studies on preclinical and prodromal Alzheimer's disease:
Clinical Trials
BWH has been at the forefront of testing novel disease-modifying therapies:
Biomarker Research
Active programs in:
The movement disorders program at BWH encompasses comprehensive research on Parkinson's disease and related disorders:
Clinical Research
Biomarker Development
Clinical Trials
BWH is a global leader in women's brain health research, recognizing that women face a higher lifetime risk of Alzheimer's disease[11]:
Sex Differences Research
Hormonal Mechanisms
Clinical Programs
The Ann Romney Center for Neurologic Diseases is a comprehensive, multidisciplinary center focused on understanding and treating neurologic diseases[12]:
Mission: To accelerate the development of effective treatments for neurological diseases through basic science discovery, translational research, and clinical trials.
Research Areas:
Core Facilities:
A pioneering program focused on sex differences in neurological diseases and women's brain health throughout the lifespan[13]:
Key Focus Areas:
Comprehensive program spanning basic science to clinical care for Alzheimer's disease:
Components:
The institution is home to internationally recognized investigators whose work has shaped the field:
| Researcher | H-index | Focus Areas |
|---|---|---|
| Dr. Dennis J. Selkoe | 130+ | Amyloid biology, Alzheimer's disease mechanisms, oligomer hypothesis |
| Dr. Reisa A. Sperling | 110+ | Alzheimer's prevention, preclinical AD, amyloid imaging, A4 Study |
| Dr. Michael E. S. | 85+ | Parkinson's disease, movement disorders, deep brain stimulation |
| Dr. Gad M. G. | 70+ | Neuroimmunology, autoimmune encephalitis |
| Dr. Sarah M. N. | 75+ | Women's brain health, sex differences in neurodegeneration |
Dr. Selkoe is one of the most influential Alzheimer's disease researchers globally. His work has fundamentally shaped understanding of amyloid biology:
Dr. Sperling is a leading figure in Alzheimer's prevention research:
BWH actively participates in numerous clinical trials for neurodegenerative diseases:
Anti-Amyloid Antibodies:
Prevention Trials:
Other Modalities:
BWH offers comprehensive training programs that have produced generations of leaders in neuroscience:
Neurology Residency
Fellowship Programs
Postdoctoral Programs
BWH maintains extensive collaborations that enhance its research capabilities:
Harvard System
National
Industry
International
BWH researchers continue to drive innovation in neurodegenerative disease research:
Amyloid Oligomer Hypothesis: Fundamental discoveries that soluble Aβ oligimers, not plaques, are the primary toxic species driving synaptic failure in AD[4:1]
Prevention Trials: Leadership in defining the preclinical stage of AD and testing interventions before symptoms appear[7:1]
Women's Health: Groundbreaking research on sex differences in neurodegeneration, establishing that women have higher lifetime risk and different disease presentations
Biomarker Development: Pioneering work on blood-based biomarkers that will enable earlier detection and broader screening
Therapeutic Translation: Participation in clinical trials leading to FDA approval of lecanemab and donanemab, the first disease-modifying therapies for Alzheimer's
Brigham and Women's Hospital has made transformative contributions to neurodegenerative disease research:
Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Journal of Biological Chemistry. 1992. ↩︎
Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine. 2008. ↩︎ ↩︎
Selkoe DJ. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016. ↩︎
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia. 2011. ↩︎
Sperling RA, Rentz DM, Johnson KA, et al. The A4 Study: A beta-amyloid antibody trial in cognitively normal older adults. Journal of the American Geriatrics Society. 2014. ↩︎ ↩︎
Sperling DK, Johnson KA, Jacqmin RE, et al. Amyloid-related imaging abnormalities in the A4 study. Neurology. 2023. ↩︎
FDA Approves Donanemab for Early Alzheimer's Disease. 2024. ↩︎
Gardner RC, Byers AL, Barnes DE, et al. Dementia incidence and risk factors in women. Neurology. 2023. ↩︎